HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Item
http://www.wikidata.org/entity/Q37368417
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy.Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.Profile of Roche's cobas® HCV tests.Resurrection of response-guided therapy for sofosbuvir combination therapies.Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.How to eliminate HCV in people who inject drugs in the USA.Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers.Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling
P2860

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Item
http://www.wikidata.org/entity/Q37368417
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HCV kinetic and modeling analy ...... vir, simeprevir or ledipasvir.
@en
HCV kinetic and modeling analy ...... vir, simeprevir or ledipasvir.
@nl
type
label
HCV kinetic and modeling analy ...... vir, simeprevir or ledipasvir.
@en
HCV kinetic and modeling analy ...... vir, simeprevir or ledipasvir.
@nl
prefLabel
HCV kinetic and modeling analy ...... vir, simeprevir or ledipasvir.
@en
HCV kinetic and modeling analy ...... vir, simeprevir or ledipasvir.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
HCV kinetic and modeling analy ...... svir, simeprevir or ledipasvir
@en
P2093
P2860
P304
P31
P356
10.1016/J.JHEP.2016.02.022
P433
P478
P50
P577
P698
P921
P932